Global life science giant Bayer has officially finalized its corporate acquisition of biopharmaceutical enterprise Perfuse Therapeutics, Inc. Following the completion of the transaction, Perfuse Therapeutics will be fully integrated and absorbed into Bayer’s operating infrastructure. The corporate merger grants Bayer unencumbered global rights to the investigational PER-001 intravitreal implant, strategically reinforcing Bayer’s pharmaceutical pipeline and expanding its established market footprint within the specialized ophthalmology sector.
The documented financial considerations, molecular mechanisms of the lead asset PER-001, advisory syndicates, and Bayer’s fiscal year 2025 financial metrics feature:
-
Transactional Capital Allocations and Success-Based Milestones:
-
Upfront Considerations: Under the definitive transactional terms announced from Berlin on June 17, 2026, Bayer disbursed an immediate upfront cash consideration of USD 300 million.
-
Aggregate Valuation Boundaries: The acquisition commands a total potential transaction value of up to USD 2.45 billion. This aggregate capital framework encompasses the initial upfront payment supplemented by back-ended, success-based milestone payments that will trigger sequentially upon validating specified clinical development and commercial criteria.
-
-
Consolidation of Global Rights for First-In-Class Asset PER-001:
-
Molecular Kinetic Profiles: Through this targeted transaction, Bayer secures full proprietary rights pertaining to the PER-001 intravitreal implant. The compound is classified as a first-in-class, sustained-release small molecule endothelin receptor antagonist engineered to optimize localized drug delivery matrices.
-
Phase II Clinical Staging: The experimental PER-001 implant is currently navigating active Phase II clinical development tracks, where investigators are evaluating its safety and therapeutic efficacy for the treatment of Glaucoma and Diabetic Retinopathy (DR)—two of the leading causes of global blindness.
-
-
Corporate Profiles of the Target and Retained Transaction Advisory Intermediaries:
-
Perfuse Therapeutics Infrastructure: Perfuse Therapeutics specializes in pioneering transformational research targeting ischemia-induced ocular diseases, enabled by its proprietary sustained-release drug delivery platform. The company maintains its corporate headquarters in South San Francisco, California, and operates dedicated R&D facilities in Durham, North Carolina.
-
Financial and Legal Counsel Syndicates: For the buyer (Bayer), BofA Securities acted as the exclusive financial advisor, and the international law firm Baker McKenzie served as legal counsel. For the target entity (Perfuse), Centerview Partners LLC functioned as the exclusive financial advisor, and Goodwin Procter LLP anchored the operational legal counsel.
-
-
Bayer Group Corporate Profile and Fiscal Year 2025 Financial Baselines:
-
Bayer operates as a global life science enterprise focused across healthcare and nutrition segments, aligned with its overarching corporate mission, “Health for all, Hunger for none.”
-
In the finalized 2025 fiscal year, the multinational group maintained a global workforce of approximately 88,000 employees and consolidated annual group sales of 45.6 billion euros. To support its innovation pipeline, Bayer’s aggregate research and development (R&D) expenditures for the 2025 fiscal year reached 5.8 billion euros.
-
Source: https://www.contractpharma.com/breaking-news/bayer-completes-acquisition-of-perfuse-therapeutics/